Question

I am a breastfeeding mother and i want to know if it is safe to use Olaparib cpd? Is Olaparib cpd safe for nursing mother and child? Does Olaparib cpd extracts into breast milk? Does Olaparib cpd has any long term or short term side effects on infants? Can Olaparib cpd influence milk supply or can Olaparib cpd decrease milk supply in lactating mothers?

Answer by DrLact: About Olaparib cpd usage in lactation

No information is available on the clinical use of Olaparib cpd during breastfeeding. Because Olaparib cpd is 82% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinued during Olaparib cpd therapy and for one month after the last dose.

Alternate Drugs

Mitoxantrone(Dangerous)
Nilotinib(Unsafe)
Erlotinib(Unsafe)
Hydroxyurea(Low Risk)
Etoposide(Dangerous)
Trastuzumab(Unsafe)
Docetaxel(Dangerous)
Doxorubicin(Dangerous)
Pazopanib(Unsafe)
Cyclophosphamide(Dangerous)
Ipilimumab(Unsafe)
Cisplatin(Unsafe)
Nivolumab(Unsafe)
Imatinib(Unsafe)
Cetuximab(Unsafe)
Busulfan(Dangerous)
Vinblastine(Dangerous)
Carboplatin(Dangerous)
Bleomycin(Dangerous)
Paclitaxel(Dangerous)
Vinorelbine(Dangerous)
Cladribine(Dangerous)
Fluorouracil(Dangerous)
Dacarbazine(Dangerous)
Alemtuzumab(Low Risk)
Rituximab(Low Risk)
Gemcitabine(Dangerous)
Dactinomycin(Dangerous)
Vincristine(Dangerous)
Letrozole(Dangerous)
Dasatinib(Unsafe)
Bevacizumab(Low Risk)
Thioguanine(Dangerous)
Tamoxifen(Dangerous)
Exemestane(Dangerous)
Nilotinib(Unsafe)
Erlotinib(Unsafe)
Pazopanib(Unsafe)
Imatinib(Unsafe)
Gemcitabine(Dangerous)
Dasatinib(Unsafe)
Orlistat(Low Risk)
Pazopanib(Unsafe)
Imatinib(Unsafe)
Dasatinib(Unsafe)
Nilotinib(Unsafe)
Erlotinib(Unsafe)
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.